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Abstract  63 
Purpose 64 
Kilovoltage Intrafraction Monitoring (KIM) is a novel software platform implemented on 65 
standard radiation therapy systems enabling real-time image-guided radiation therapy 66 
(IGRT). In a multi-institutional prospective trial, we investigated whether real-time IGRT 67 
improved the accuracy of the dose prostate cancer patients received during radiation therapy. 68 
Methods and Materials 69 
Forty-eight patients with prostate cancer were treated with KIM-guided Stereotactic Ablative 70 
Radiation Therapy (SABR) with 36.25 Gy in five fractions. During KIM-guided treatment 71 
the prostate motion was corrected for by either beam g ting with couch shifts or multileaf 72 
collimator tracking. A dose reconstruction method was used to evaluate the dose delivered to 73 
the target and organs at risk with and without real-time IGRT. Primary outcome was the 74 
effect of real-time IGRT on dose distributions. Secondary outcomes included patient-reported 75 
outcomes and toxicity. 76 
Results 77 
Motion correction occurred in ≥1 treatment for 88% of patients (42/48) and 51% of 78 
treatments (121/235). With real-time IGRT, no treatments had prostate CTV D98% dose 5% 79 
less than planned. Without real-time IGRT, 13 treatments (5·5%) had prostate CTV D98% 80 
doses 5% less than planned. The prostate CTV D98% dose with real-time IGRT was closer to 81 
the plan by an average of 1·0% (range -2·8% to 20·3%). Patient outcomes show no change in 82 
the 12-month patient reported outcomes compared with baseline and no grade ≥3 GU or GI 83 
toxicities.  84 
Conclusion 85 
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Introduction  91 
Radiation therapy is an effective treatment option in the management of prostate cancer.1 92 
Accurate delivery of radiation dose is of fundamental importance in radiation oncology.  93 
Technical advances in radiation therapy technology have improved cancer treatment 94 
outcomes. These advances are evident for prostate cancer where image-guided radiation 95 
therapy (IGRT) and intensity modulated radiation therapy (IMRT) have independently 96 
demonstrated improved tumor control and lower rates of late rectal toxicity.2-6 However, 97 
prostate motion during radiation therapy may shift t e tumor outside the beam, 98 
simultaneously reducing target dose and exposing normal tissues to increased radiation doses. 99 
The deleterious effects of motion for prostate cancer has led the American Society for 100 
Radiation Oncology to recommend ‘A precise ability to localize the target tumor is ess ntial 101 
to fully benefit from stereotactic body radiation therapy techniques’.7 As the duration of 102 
prostate radiation therapy is compressed initially from around 40 treatments, to closer to 20, 103 
and more recently down towards five or fewer treatments, the importance of accurate 104 
treatment grows.8-10 Clinical trials seeking to validate stereotactic ablative radiation therapy 105 
(SABR) approaches are underway.11 106 
 107 
Correction for interfraction motion has become standard of care, but management of 108 
intrafraction motion is not widely used despite evidence of prostate movement even over the 109 
few minutes which treatment takes.12  Real-time IGRT, where the cancer target position is 110 
continuously monitored during treatment, was clinically pioneered over 20 years ago.13 111 
Prostate cancer patients treated with real-time IGRT showed significantly lower bowel 112 
morbidity and improved health-related quality of life than a comparator cohort treated 113 





superior target dose coverage compared to if they had been treated without real-time 115 
IGRT.15,16 116 
 117 
Several commercially available technologies have been developed to perform real-time 118 
IGRT17 but require extra hardware and/or per patient expendables.  To improve widespread 119 
access, real-time IGRT would ideally be performed using the equipment that already exists 120 
on standard linear accelerators (linacs).  A review of real-time IGRT on standard-equipped 121 
cancer radiation therapy systems identified three clinically applied technologies for prostate 122 
and liver cancer SABR patients with further methods under development that could be 123 
clinically used for real-time IGRT.17 More recently real-time IGRT for spinal SABR was 124 
implemented on a standard linac.18 Together these advances demonstrate a trajectory of real-125 
time IGRT becoming more widely available for patiens receiving SABR.  126 
 127 
One of these clinically applied technologies, Kilovoltage Intrafraction Monitoring (KIM), the 128 
technology under investigation in this trial, uses the existing x-ray system to measure the 129 
target translation and rotation during radiation therapy.19 KIM is an in-house developed 130 
software-based medical device. It is integrated into Elekta and Varian linacs using a computer 131 
connected to the linac to read the images and treatment data in real-time and give the target 132 
position and rotation measurements, along with the decision of whether a couch shift is 133 
needed when gating is used, or directly sending the target position measurements to the 134 
multileaf collimator (MLC) tracking system when this correction method is used. In an 135 
analysis of the accuracy and precision of the KIM system, the in-treatment measurements of 136 
44 patients were analysed using the kV and MV images acquired during treatment using 137 
triangulation.  The centroid geometric accuracy andprecision of the KIM system during the 138 





0.1 ± 1.4° and -0.1 ± 1.0° for rotation in the AP, LR and SI directions respectively.20  The 140 
measured latency is 350 ms.21 When KIM is used with gating the correction workflow 141 
depends on the type of linac used. For Elekta Synerg  and Varian Trilogy linacs, KIM 142 
computes the couch shift based on the last known prostate position, and the radiation 143 
therapists shift to the couch to the new coordinates. On Varian TrueBeam linacs, the system 144 
requires additional kV-kV imaging prior to implementing the shift. When KIM is used with 145 
MLC tracking KIM’s 3D position is streamed to the MLC tracking program. This program 146 
combines the position information with the plan to adjust the MLC leaf positions to the 147 
moving target.19 The promising findings of the use of KIM in a single institution pilot study 148 
(NCT01742403) stimulated the development of the multi-institutional Trans-Tasman 149 
Radiation Oncology Group (TROG) 15.01 Stereotactic Prostate Ablative Radiation Therapy 150 
with KIM (SPARK) trial (NCT02397317).22 151 
 152 
In this study we investigated whether real-time IGRT improved the accuracy of the dose 153 





Methods and Materials 155 
Trial design  156 
The SPARK trial was based on the KIM real-time IGRT method for treatments requiring 157 
correction for target motion, with the protocol published separately.22 We considered a 158 
treatment with KIM-guided motion correction (real-time IGRT) a success if the estimated 159 
delivered patient dose distribution was closer to the planned values than the estimated dose 160 
distribution without real-time IGRT. The dose metric for reporting target doses in the 161 
presence of motion is not explicitly detailed in ICRU Report 83,23 so the prostate dose values 162 
assessed were the dose to 98% (D98%) of the clinical target volume (CTV). The rectal and 163 
bladder doses were chosen to be the volume of the rectum receiving above 30 Gy (V30Gy). 164 
To put the results into context, a 5% dose difference between the planned dose and that 165 
delivered to the patient has long been considered clinically meaningful.24 166 
 167 
The trial was approved by a human research ethics committee (HREC/15/HNE/216), 168 
prospectively registered and all patients provided written informed consent. 169 
 170 
Radiation treatment and dose assessment details 171 
All patients had three intraprostatic gold markers inserted.  Patients were prescribed 36.25 Gy 172 
to the PTV in five treatments. Patients were treated with multi-arc VMAT with 6 MV or 10 173 
MV energy beams on Elekta Synergy, Varian Trilogy or Varian TrueBeam linacs with KIM 174 
implemented. Prior to each treatment the patient ana omy acquired with CBCT was aligned to 175 
the radiation beam via their gold markers.  During treatment, the target motion was corrected 176 
in real-time by implementing either beam gating with couch shifts if motion exceeded 2-3 177 
mm motion thresholds for ≥5 seconds or MLC tracking.25 The gating thresholds were chosen 178 





tracking has no correction threshold and any detectd motion results in a beam shift. MLC 180 
tracking was only available at one institution for the study and was used to correct for motion 181 
for all 10 patients treated at that institution. The remaining 34 patients treated at four separate 182 
institutions used beam gating with couch shifts to correct for motion. For 44/48 patients the 183 
estimated dose distribution that was delivered to the patients with real-time IGRT was 184 
estimated by generating motion-encoded plans that mimicked prostate motion as multiple 185 
isocenter shifts and replaced the planned MLC positions with actual positions for MLC 186 
tracking.26 The motion-encoded plans were recalculated by the treatment planning system on 187 
the planning CT scans. For the remaining four patients where a different treatment planning 188 
system was used, the dose reconstruction was performed by measuring the mean position of 189 
the target with respect to the isocenter for each treatment arc. To compute the dose to the 190 
patient in simulated treatments without real-time IGRT, the KIM-measured prostate motion 191 
without couch corrections was used as the input to the dose reconstruction method. This 192 
process resulted in three dose distributions for each treatment – the planned dose, the 193 
estimated delivered dose with real-time IGRT and the estimated delivered dose without real-194 
time IGRT. As such, every treatment was able to act as both a case and an internal control for 195 
comparative purposes. 196 
 197 
The dose reconstruction was performed on the planning CT scan rather than the daily CBCT 198 
scan for each fraction. The advantage of using the planning CT is that deformable registration 199 
is not required, and the dose calculation issues on CBCT are avoided. However, the 200 
disadvantage is that the changes in the target and organs-at-risk are ignored.  Nevertheless, 201 
the use of the planning CT scan for the dose reconstruction is a limitation. Had the CBCT 202 
scan been used, the motion that occurred during the treatment after the CBCT scan means 203 





Ideally this process would be based on volumetric imaging information at each time point 205 
during the treatment, with robust deformable registration and dose calculation.  Until real-206 
time volumetric imaging during treatment becomes a reality, there will be limitations in the 207 
dose accumulation process. The QUANTEC vision reference on dose accumulation 208 
highlights the need for accelerated research and development into auto-segmentation, 209 
deformation, modeling, dose accumulation, dose calcul tion in complex environments, and 210 
methods of estimating the uncertainty in the accumulated dose distribution over the course of 211 
therapy. 27 212 
 213 
To improve anatomic consistency between simulation and treatment the trial’s Radiotherapy 214 
Planning, Delivery and Quality Assurance procedures document recommended both a 215 
bladder protocol to regulate bladder volume and a bowel protocol. The implementation of the 216 
protocols was according to each institution’s practice. 217 
 218 
A quality assurance program was implemented for each of the three novel technologies used 219 
in this trial, KIM,21 MLC tracking28 and time-resolved dose reconstruction.26  220 
 221 
Patient outcomes  222 
A secondary outcome of the SPARK trial was to measure patient treatment outcomes (PROs) 223 
using the Expanded Prostate Cancer Index Composite (EPIC)-2629 instrument. Genitourinary 224 
(GU) and gastrointestinal (GI) physician-graded toxicity were measured using the Common 225 
Terminology Criteria for Adverse Events (CTCAE) v4·0 scale.30 Prostate-specific antigen 226 
(PSA) levels were recorded with biochemical PSA failure defined using the ASTRO Phoenix 227 






Patient characteristics 230 
Forty-eight patients with prostate cancer were treated with KIM-guided SABR at five 231 
institutions. The patient characteristics and treatment information are summarized in Table 1. 232 
 233 
Patient dose results 234 
The scheme used in the SPARK trial is shown in Figure 1. KIM was used in 235 SPARK trial 235 
treatments. Five treatments were delivered without KIM because of technical issues: hard 236 
drive full (two treatments), pre-treatment/KIM position discrepancy, overlapping markers and 237 
imaging noise. For the treatment with the pre-treatment/KIM position discrepancy there was 238 
>1 mm positioning difference between KIM and the kV/k  match. For this treatment, the 239 
clinical decision was made to treat the patient using the standard of care (triggered imaging) 240 
rather than using KIM. As the kV/kV match was performed at a different time than the KIM 241 
positioning, the probable cause of this discrepancy was prostate motion. Real-time IGRT 242 
using KIM-guided motion correction occurred in at least one treatment for 88% of the 243 
patients (42/48) and 51% of the treatments (121/235).  244 
 245 
Waterfall plots of the dose-volume points with and without real-time IGRT for the prostate 246 
(CTV D98%), rectum (V30Gy) and bladder (V30Gy) are shown in Figure 2 for the 121 247 
treatments with real-time IGRT. With real-time IGRT, the number of treatments with the 248 
prostate CTV dose 5% less, or the rectal or bladder ose 5% more than the planned dose was 249 
0, 0 and 0, respectively. Without real-time IGRT, the number of treatments with the prostate 250 
CTV dose 5% less, or the rectal and bladder dose 5% more than the planned dose was 13, 4 251 





target dose coverage and rectal sparing were largest with real-time IGRT are shown in 253 
Figure 3. 254 
 255 
The prostate CTV D98% dose with real-time IGRT was clo er to the plan in 51% (62/121) of 256 
the treatments by an average of 1·0% (range -2·8% to 20·3%). The rectal V30Gy dose with 257 
real-time IGRT was closer to the plan in 86% (104/121) of the treatments by an average of 258 
1·5% (range -1·2% to 9·7%).  The bladder V30Gy dose with real-time IGRT was closer to 259 
the plan in 90% (109/121) of the treatments by an average of 1·8% with the range from -260 
2·3% to 14%.  When the dose with real-time IGRT wasorse, the difference was small, for 261 
the three metrics above the maximum detriment was -2·8%. When the dose with real-time 262 
IGRT was better, large improvements were observed for the outlier treatments. Of the three 263 
metrics above, the largest benefit over 20%. The prostate PTV D95% results are shown in the 264 
supplementary material. 265 
 266 
The treatment delivery times with MLC tracking were similar to that of the original VMAT 267 
plan as there is negligible overhead with the MLC tracking software used. The treatment 268 
times were increased when using beam gating with couch shifts. This increase varied by the 269 
type of linac used, ranging from 30 seconds to 2 minutes per couch shift. There were 92 270 
gating events for the treatments of the 38 patients treated with the couch correction strategy.  271 
 272 
Patient outcomes  273 
One-year PROs, GU and GI physician-graded toxicity and PSA measurements are shown in 274 
Figure 4 with at least 43 of the 48 patients included. For the PROs in some domains there is a 275 
short-term drop, however by 12 months the outcomes ar  the same as baseline. Two grade 2 276 





toxicity was observed. All adverse events are included even if not considered to be related to 278 
treatment. Biochemical failure has been observed in one patient 42 months post-treatment. 279 
Assessment via PSMA-PET showed widespread lymphadenopathy and a solitary bone 280 






We employed KIM to enable real-time IGRT on a standard linac for the treatment of 48 283 
prostate cancer SABR patients. We investigated where the dose delivered to patients with 284 
real-time IGRT was better than the dose that would have been delivered to patients without 285 
real-time IGRT. First, we showed that this technology can be successfully implemented 286 
across several centers, vendors and clinical platforms, demonstrating both the flexibility and 287 
practicality of the KIM software device in transforming standard cancer radiation therapy 288 
systems into real-time IGRT systems that continuously monitor the target position and 289 
rotation during treatment.  Second, in 42 of the 48 patients and half (51%) of the treatments, 290 
significant movement occurred during the treatment tha would have been undetected without 291 
real-time IGRT.  Third, the trial outcome was positive: with real-time IGRT, the number of 292 
treatments with the prostate CTV dose 5% less, or the ectal and bladder dose 5% more, than 293 
the planned dose was 0, 0 and 0, respectively, compared with 13, 4 and 14, without real-time 294 
IGRT (Figure 2). These results give confidence thatwith real-time IGRT the delivered dose 295 
is similar to the planned dose.  When coupled with the promising early PROs that compare 296 
favorably with the five-treatment arm of the recently reported RTOG 0938 trial,32 we believe 297 
this trial demonstrates the value of real-time IGRT in delivering more accurate radiation 298 
therapy.  299 
 300 
SABR is an emerging option for prostate radiation therapy, and the evidence base continues 301 
to grow.  A recent meta-analysis of ten series including 2142 patients with a median of 7 302 
years follow-up showed overall biochemical control rates of over 90% for a low to 303 
intermediate risk population, and very low rates of evere toxicities.9 The Scandinavian 304 





between a conventional regimen or a seven treatment SABR alternative.33 Given the multiple 306 
randomized studies maturing in this area, we expect th  evidence base to only get stronger.11   307 
 308 
Management of organ motion is critical for accurate delivery of prostate SABR, and also in 309 
other tumor sites where respiratory motion is present, such as liver and pancreas tumors.  We 310 
are currently exploring expanding the use of KIM for enabling real-time IGRT into these 311 
other tumor sites. Two limitations of the KIM real-time IGRT method are the reliance on 312 
implanted markers and the imaging dose (estimated to be 440 mGy for the entire treatment34). 313 
A planned future development is to use deep learning to personalize the KIM system to 314 
minimize the marker sizes and imaging doses whilst retaining robustness and accuracy for 315 
each patient. Ultimately, developing accurate soluti ns to target internal tumors without 316 
implanted markers using standard cancer radiation therapy systems would further reduce 317 
barriers to the widespread adoption of real-time IGRT technologies such as KIM. 318 
 319 
One feature of the SPARK clinical trial is the use of an estimate of the delivered dose to the 320 
patient as a surrogate for clinical outcome. The ability to compute the estimated delivered 321 
dose during each treatment is a byproduct of measuring real-time target motion from systems 322 
such as KIM. Jaffray et al. describe the importance of accurately estimating the dose 323 
delivered to the patient during a treatment, rather an the assumption that the delivered dose 324 
to the patient equaled the treatment plan.35,36 Accurate patient dose estimation not only 325 
improves radiation outcomes modelling but will also address the technical demands of the 326 
adaptive radiation therapy paradigm. A broader limitation of our study is that it is not 327 
randomized.  However, given that each patient can effectively act as their own control in 328 





heterogeneity.  Further data maturation will be needed to report efficacy and toxicity 330 
endpoints. 331 
 332 
Another feature of the KIM system is the ability to measure rotation of the target in real-time 333 
in addition to translational displacement. In the SPARK trial, rotation observed prior to 334 
treatment was corrected at some centers via a six degree of freedom couch, and in other 335 
centers by realigning the patient. We have modelled th  dosimetric impact of uncorrected 336 
rotations, but given the prostate approximates a sphere, with a relative sphericity of ~0.8 , the 337 
dosimetric impact of rotation is smaller than for more elongated tumor volumes.37 If an 338 
elongated tumor rotates, it is more likely the tumor will move outside the planned margins 339 
where the dose drops off quickly. If an approximately spherical tumor rotates, the rotated 340 
tumor is more likely to be inside the planned margins and remain in the high dose volume. 341 
Rotation may prove to be important as KIM is implemented for real-time IGRT of other 342 
tumor sites. 343 
 344 
In this study two forms of correction for motion were used, either beam gating with couch 345 
shifts or MLC tracking. Future work could include an nalysis of the dosimetric and 346 
workflow differences between these two motion correction strategies.   347 
 348 
Conclusion 349 
The SPARK trial primary outcome showed that real-time IGRT is clinically useful in 350 
improving the accuracy of the prostate and rectum dose in the presence of target motion. 351 
With the use of KIM enabling real-time IGRT on a stndard linac, this approach holds 352 
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Figure Legends 467 
Figure 1. The scheme used in the SPARK trial to investigate if r al-time IGRT improves 468 
dose distributions for prostate cancer SABR patients.  469 
 470 
Figure 2.  Waterfall plots of the difference in dose from the plan for the treatments with 471 
interventions with real-time IGRT (blue) and without real-time IGRT (red) (A) prostate (CTV 472 
D98%), (B) rectum (V30Gy), and (C) bladder (V30Gy). The 5% dose difference line is 473 
shown.  474 
 475 
Figure 3.  (A) Isodose distributions showing the treatments with the largest benefit for real-476 
time IGRT for the prostate target and rectal sparing. (B) and (C) Dose volume histograms 477 
with and without real-time IGRT for the patients from the isodose in (A) upper and lower 478 
panels respectively.  479 
 480 
Figure 4.  (A) Median and Interquartile range (IQR) of EPIC-26 patient reported outcomes, 481 
n=43-45 depending on domain. (B) Prostate Specific Antigen (PSA) levels (ng/ mL). Box 482 
plot represents median with IQR and whiskers are the minimum/maximum values, n=47. (C) 483 
CTCAE v4.0 genitourinary and (D) gastrointestinal toxicities, n=48.  All adverse events are 484 
included even if not considered to be related to treatment.  485 
 486 
Table 1. Patient characteristics and treatment information for the “Blinded for review” trial.  
 
Age in years at recruitment (median, range) 69 (57-81) 
Risk status  
Low-risk Disease  
PSA<10 ng/mL, Gleason score 6 and stage T1 or T2a 
2/48 (4%) 
Intermediate-risk Disease 
PSA 10-20 ng/mL, Gleason score 7 or stage T2b-c 
46/48 (96%) 
Eastern Cooperative Oncology Group performance status  
0 45/48 (94%) 
1 3/48 (6%) 
KIM-guided motion correction strategy  
Gating with 2-3 mm threshold 38/48 (79%) 
MLC adaptation 10/48 (21%) 
Cancer radiation therapy system used with KIM  
Elekta Synergy 4/48 (8%) 
Varian Trilogy 10/48 (21%) 




48 patients with 
intraprostatic fiducials
240 treatments delivered 
(5/patient)
235 treatments delivered 
with KIM
121 treatments involving 
motion correction in 42 
patients
Dose distributions analyzed 
for these 121 treatments
Dose calculated with real-
time IGRT
Dose estimated without 
real-time IGRT
5 treatments delivered 
without KIM
Adverse events, Quality of 
Life meaures, Prostate 
Specific Antigen levels for all 
patients treated (as 
available at current date)
1 patient with migration of 
fiducials outside the 
prostate
Compared calculated and 
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